

Citation for published version:

Ilaria Passarini, Sharon Rossiter, John Malkinson, and Mire Zloh, 'In Silico Structural Evaluation of Short Cationic Antimicrobial Peptides', *Pharmaceutics*, Vol. 10 (3): 72, June 2018.

DOI:

<https://doi.org/10.3390/pharmaceutics10030072>

Document Version:

This is the Published Version.

Copyright and Reuse:

© 2018 by the authors. Licensee MDPI, Basel, Switzerland.

This is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license

<http://creativecommons.org/licenses/by/4.0/>

Enquiries

If you believe this document infringes copyright, please contact Research & Scholarly Communications at rsc@herts.ac.uk

Article

In Silico Structural Evaluation of Short Cationic Antimicrobial Peptides

Ilaria Passarini ¹, Sharon Rossiter ¹ , John Malkinson ² and Mire Zloh ^{1,3,4,*} 

¹ School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK; i.passarini@herts.ac.uk (I.P.); s.rossiter@herts.ac.uk (S.R.)

² UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, UK; j.malkinson@ucl.ac.uk

³ Faculty of Pharmacy, University Business Academy, Trg mladenaca 5, 21000 Novi Sad, Serbia

⁴ NanoPuzzle Medicines Design, Business & Technology Centre, Bessemer Drive, Stevenage SG1 2DX, UK

* Correspondence: zloh@live.co.uk

Received: 18 May 2018; Accepted: 12 June 2018; Published: 21 June 2018



Abstract: Cationic peptides with antimicrobial properties are ubiquitous in nature and have been studied for many years in an attempt to design novel antibiotics. However, very few molecules are used in the clinic so far, sometimes due to their complexity but, mostly, as a consequence of the unfavorable pharmacokinetic profile associated with peptides. The aim of this work is to investigate cationic peptides in order to identify common structural features which could be useful for the design of small peptides or peptido-mimetics with improved drug-like properties and activity against Gram negative bacteria. Two sets of cationic peptides (AMPs) with known antimicrobial activity have been investigated. The first reference set comprised molecules with experimentally-known conformations available in the protein databank (PDB), and the second one was composed of short peptides active against Gram negative bacteria but with no significant structural information available. The predicted structures of the peptides from the first set were in excellent agreement with those experimentally-observed, which allowed analysis of the structural features of the second group using computationally-derived conformations. The peptide conformations, either experimentally available or predicted, were clustered in an “all vs. all” fashion and the most populated clusters were then analyzed. It was confirmed that these peptides tend to assume an amphipathic conformation regardless of the environment. It was also observed that positively-charged amino acid residues can often be found next to aromatic residues. Finally, a protocol was evaluated for the investigation of the behavior of short cationic peptides in the presence of a membrane-like environment such as dodecylphosphocholine (DPC) micelles. The results presented herein introduce a promising approach to inform the design of novel short peptides with a potential antimicrobial activity.

Keywords: cationic antimicrobial peptides (AMPs); amphipathic conformation; molecular dynamics; protein structure prediction; dodecylphosphocholine (DPC) micelles

1. Introduction

The surge of multidrug resistant microorganisms and the lack of new antibiotics present a major challenge to modern medicine [1]. Naturally-occurring cationic peptides often possess antimicrobial properties [2] and represent a promising class of lead compounds to be selected for the design of new antibiotics. However, of the nearly 5000 cationic antimicrobial peptides (AMPs) described to date, fewer than 100 are currently undergoing clinical trials [3], possibly due to the challenges related

to the development of protein-based drugs. Several resources are available for predicting the 3D conformations of peptides, such as the online software PEP-FOLD [4], as well as their antimicrobial potential [5]. Three pathways are usually followed in efforts to obtain novel peptides: modification of existing templates through bioinformatics methods, often looking at the modification of the primary sequences; biophysical modelling, such as molecular dynamics simulations, which can also take into account the effect of the environment on the conformations; and screening of libraries which may focus on the structure activity relationship (SAR) [6,7]. However, the complexity of problems associated with *in vivo* application of these molecules and understanding their mechanism of action calls for a continuous improvement of these methods, with the aim to obtain antimicrobial agents with improved pharmacological profiles.

Despite their mechanism(s) of action still not being fully understood, it is broadly accepted that AMP play a role in the alteration of the bacterial membrane and wall systems, with the consequent disruption of the proton motive force and the general viability of the organism [8]. Although the experimental studies, such as NMR spectroscopy, can provide information on the structures and orientation of peptides bound to micelles, *in silico* studies such as molecular dynamics (MD) are often utilized for the study of the interaction of AMPs with membrane-like structures [9]. Such approaches are important for the design of the novel peptides as the hypothesis can be tested before time-consuming and resource-demanding synthesis and purification.

Therefore, the aim of our work was to investigate both the sequences and conformations of AMPs to possibly identify common features that can inform the design of novel short peptides or small peptide mimetics with antimicrobial potential and a more favorable pharmacokinetic profile. To this aim, a library of active peptides with known 3D structures was initially created and clustered and the centroids analyzed. This confirmed the experimental evidence that the majority of these molecules often contain basic amino acid residues in close proximity to aromatic residues and that they assume an amphipathic conformation [2,5]. Furthermore, it was shown that their predicted conformations are in excellent agreement with those experimentally observed in solution. The structures of the second set of AMPs, with no experimental data about their conformation, were predicted *in silico* before being clustered. The judicious analysis of the centroids of the most populated clusters suggested that these peptides with activity against Gram negative bacteria also assume amphipathic conformations, although no particular predominance of basic or aromatic amino acid residues was apparent. Finally, it was demonstrated that the interactions between short AMPs and a membrane-like environment can be investigated *in silico* using the predicted structure as a starting point. The results of this work provide important insights in structural features of AMPs with activity against Gram negative bacteria and indicate that a combination of *in silico* approaches can aid efforts to design novel AMPs.

2. Materials and Methods

2.1. Data Collation

The first dataset of peptides with known 3D structures was created using a search for a string “antimicrobial peptides” in the protein databank (PDB) [10]. The search results were filtered to select structures derived from solution-state NMR. All cyclic peptides, dimers or multimers and peptide-receptor complexes were not considered and no other specific restrictions, e.g., size, charge, origin or mechanism of action, were included in the search. All peptides were active either against Gram positive and/or negative strains. A library of 117 PDB entries was thus created based on results retrieved at the time of the search.

All short peptides were shortlisted from this first set, namely those under 15 residues in length. This resulted in a list of 12 molecules, which were then further divided into two groups, containing structures determined either in the presence (Table 1) or absence (Table 2) of micelles.

Table 1. Sequences of antimicrobial peptides whose 3D structures were determined in the presence of micelles. For all entries, the NMR data were acquired in the presence of dodecylphosphocholine (DPC) micelles, with the exception of 2MAA which was obtained in presence of lipopolysaccharide (LPS) micelles instead.

PDB ID	Peptide	Sequence	AA
2MJT	Anoplin [11]	GLLKFIKWLL-NH ₂	11
1G89	Indolicidin [12]	ILPWKWPWWPWRR-NH ₂	13
2F3A	LLAA [13]	RLFDKIRQVIRKF-NH ₂	14
1D7N	Mastoparan X [14]	INLKALAAALAKKIL-NH ₂	15
2JQ2	PW2 [15]	HPLKQYWWRPST	12
2JMY	CM15 [16]	KWKLFKKIGAVLKVL	15
2MAA	Temporin-1 Ta [17]	FLPLIGRVLSGIL (LPS micelles)	13
1D6X	Tritrpticin [18]	VRRFPWWWPFLRR	13
1T51	IsCT [19]	ILGKIWEGIKSLF-NH ₂	14

Table 2. Sequences of antimicrobial peptides whose 3D structure has been determined in the absence of micelles.

PDB ID	Peptide	Sequence	AA
2L24	Not named [20]	IFGAIAGFIKNIW-NH ₂	14
2N9A	Decoralin-NH ₂ [21]	SLLSLIRKLIT-NH ₂	12
2NAL	Retro-KR-12 [22]	RLFDKIRQVIRK	12

A second set of short cationic antimicrobial peptides was created through a literature search and cross-referenced against existing on-line databases, such as the “Antimicrobial Peptide Database” [23]. They were required to be active against Gram negative strains with minimum inhibitory concentrations (MICs) below 128 µg/mL, have a primary sequence ranging between 9 and 15 amino acids and carry at least one net positive charge at neutral pH. As opposed to the first set of peptides, no information about their conformations was available in the literature at the time of the data collation.

2.2. Structure Prediction and Molecular Dynamics Simulation

The 3D conformations of all short peptides from the first set (containing 15 amino acid residues or fewer) were initially predicted using the online software PEP-FOLD [4]. Due to software limitations, the conformation can only be predicted for peptides with a primary sequence between 9 and 36 residues. The primary sequence is submitted using a single letter code and the program predicts the 3D conformation by assembling predicted conformations of short local sequences using a greedy procedure driven by a coarse-grained energy score. The results were then imported into Maestro as .pdb files and the C-terminus was amidated when appropriate.

The initial predictions were then submitted to molecular dynamics (MD) simulations using Desmond [24] and the OPLS 2005 all atoms force field [25] (Maestro version 11.0.014, Schrödinger LLC, New York, NY, USA). All peptides were prepared for the simulation using Protein Preparation wizard by adding all hydrogen atoms and setting the protonation states of all ionizable groups for pH 7. Each peptide was fully solvated using an explicit solvent (SPC water model) with the box size 10 Å larger than the size of the molecule in all directions using System Builder. Ions were added to mimic physiological conditions with a 0.15 M concentration of NaCl, and including Cl⁻ as counter ions to neutralize the system. Each system was minimized until the norm of the energy gradient was <0.1 kcal/mol. Furthermore, the whole system was simulated for 10 ns at 300 K under constant pressure and temperature (NPT) conditions. The results of the simulations were saved as trajectories of structures at every 5 ps. Trajectories and structures extracted from the final frame were used for HC and analysis. Conformations at 0, 1.2 and 10 ns were superimposed on the experimental PDB structures using the α-carbon alignment tool featured in Maestro.

The aforementioned method was also applied for the 3D structures prediction of peptides from the second set, namely by subjecting the PEP-FOLD predicted conformations to 1.2 ns MD simulations under the same conditions reported earlier.

2.3. Hierarchical Clustering

Hierarchical clustering (HC) was conducted on the two different sets of peptides, with experimentally-determined and predicted structures. A list of the 3D structures in pdb format was generated as a text file and submitted to the MaxCluster software for clustering [26]. HC with average linkage based on root mean square deviation (RMSD) was performed, with a threshold set at 700 for the first set and 800 for the second. The centroids of the most populated clusters were analyzed, looking for common features in the amino acid sequences and in the tertiary structures. The surfaces of all peptides were also generated using the structure analysis tool featured in Maestro (version 11.0.014, Schrödinger LLC, New York, NY, USA) to evaluate and compare surface hydrophobic and hydrophilic properties.

2.4. Molecular Dynamics Simulation of Peptides in the Presence of Micelles

Finally, the short antimicrobial peptide Anoplin was selected as a case study for the investigation of the behavior of short AMPs in presence of a membrane-like environment [27]. The NMR structure of Anoplin combined with dodecylphosphocholine (DPC) micelle is available as PDB entry 2MJT [11]. In order to test the suitability of this system and of the software used, 2MJT PDB file was initially downloaded (including the micelle). A fully solvated system was prepared with 10 Å water buffer, 0.15 M NaCl, and Na⁺ and Cl⁻ as counter ions. A 10 ns MD simulation was conducted using Desmond and OPLS2005 force field (Maestro version 11.0.014, Schrödinger LLC, New York, NY, USA). This was followed by a set of MD simulations on a system built to recreate the experimental conditions described by Uggerhoj [11]. Therefore, a micelle formed by 65 DPC molecules was initially built using Packmol [28]. The terminal carbon atoms of the hydrophobic chains were constrained in the center of the box around a sphere of 4 Å radius, so that the hydrophobic tails would point towards the centre of the micelle. Conversely, all nitrogen atoms belonging to the choline moiety were constrained around a sphere of radius 18 Å, so that the polar heads of 20 Å long DPC molecules would point towards the external aqueous environment. A 10-mM phosphate buffer was also included, with three diphosphate and one monophosphate molecules randomly distributed in the system. Finally, a structure of Anoplin was also included at a random position 10 Å away from the micelle. Two different systems were built with Anoplin (1) in an extended conformation and (2) in a conformation predicted using PEP-FOLD. A water buffer of 80 Å sides was built around the systems using System Builder in Desmond, including 15 mM NaCl and relevant counter ions. 10 ns simulations were then run using Desmond with the OPLS2005 force field [25], keeping constant atmospheric pressure (1.01325 bar) and room temperature (300 K).

3. Results

3.1. Investigation of a Set of Antimicrobial Peptides with Known Conformation

A set of 117 PDB entries corresponding to NMR-derived conformations of antimicrobial peptides was created (Table S1). These entries were clustered according to the lowest possible root mean square difference (RMSD) in an “all vs. all” fashion (Table 3). The four most populated clusters with their centroids were analyzed in detail, while the structures of the remaining clusters’ centroids are shown in Figure S1.

The 3D conformations of all peptides containing 15 residues or fewer were then predicted, by submitting the conformations obtained through the online software PEP-FOLD to 10 ns MD simulations. The backbones of the conformations simulated at 10, 1.2 and 0 ns (the latter corresponding to the PEP-FOLD prediction) were superimposed to the corresponding PDB entries, which were obtained from NMR experiments. The structures were compared using RMSD (Table 4).

Table 3. Clusters obtained from hierarchical clustering with threshold set at 700.

Cluster	Number of AMPs in Cluster	RMSD	Centroid PDB ID
1	24	417.506	5MMK
2	14	466.125	2MXQ
3	13	270.961	2NDC
4	13	155.284	2RTV
5	11	183.288	5YKL
6	8	626.605	2LG4
7	7	144.665	2MUH
8	7	3.293	2MLU
9	6	500.236	5UI7
10	5	401.027	2MFS
11	3	333.869	1FRY
12	3	666.667	1ZRX
13	2	1.289	2LS1
14	1	0.000	2N0V

Table 4. The root mean square difference (RMSD) values resulting from the superposition of the peptide α -carbon atoms of the *in silico* predicted conformations (PEP-FOLD predicted and extracted from trajectory at 1.2 and 10 ns) on the corresponding experimental determined conformation extracted from the PDB.

PDB Entry	Number of AA	RMSD (Å)		
		PEP-FOLD	1.2 ns	10 ns
2MJT	11	0.4461	0.1793	2.8464
1G89	13	6.4019	6.3364	10.5531
2F3A	14	1.6773	1.4999	1.6041
1D7N	15	2.1988	2.2371	3.1736
2JQ2	12	3.1997	3.5588	3.5946
2JMY	15	1.3061	1.3681	3.0161
2MAA	13	2.0415	2.6618	4.0329
1D6X	13	3.6692	3.3713	4.0437
1T51	14	1.9547	2.4822	2.9325
2L24	14	1.0952	3.0831	5.0254
2N9A	12	1.2719	2.2212	2.6661
2NAL	12	1.3380	1.8398	2.4378

3.2. Investigation of a Set of Antimicrobial Peptides with No Known Conformation

A search for short cationic antimicrobial peptides active against Gram negative strains was conducted, providing a set of 63 molecules with no experimental available data on their 3D structures (Table S2). Their initial conformations were predicted using PEP-FOLD, and they were used to build the systems for 1.2 ns MD simulations. The structures extracted from the final frames of corresponding trajectories were clustered in an “all vs. all” fashion by calculating the lowest possible RMSD. This provided 13 clusters, one of which contained 25 peptides and one 20 (Table 5). All other clusters were only formed by one to three peptides, and the corresponding centroids are shown in Figure S10.

Table 5. Clusters obtained from hierarchical clustering with threshold set at 800.

Cluster	Centroid	Size	RMSD
1	VCP-VT1	25	321.152
2	UyCT1	20	550.390
3	Andreonicin C1	3	666.667
4	Tigerin3	2	3.302
5	CP-11C	2	500.00
6	Jelleine II	2	500.00
7	Urechistachykinin I	2	0.320
8	Peptide AN5-1	2	0.323
9	Tigerin 1	1	0.000
10	Cn-AMP1	1	0.000
11	Astadidin 2	1	0.000
12	PGLa-H	1	0.000
13	Odirranain-V1	1	0.000

3.3. A System to Study the Interaction of Short Antimicrobial Peptides with a Membrane-Like Structure

A system to study the behaviour of short cationic peptides in presence of a membrane-like environment, such as dodecylphosphocholine (DPC) micelles, was evaluated. The PDB entry 2MJT was selected as the template, as it corresponds to the NMR-derived conformation of the antimicrobial peptide Anoplin in the presence of DPC micelles. Firstly, 10 ns MD simulation on the system was performed in aqueous buffer to test the suitability of the software. The conditions of the NMR experiment were then recreated *in silico*. An MD simulation of a system that included the extended structure of Anoplin did not result in a folded peptide as expected, as the simulation time of 1.2 ns was short. In fact, the extended peptide would not provide an adequate interface enabling the formation of favourable interactions with the micelle. However, when the PEP-FOLD predicted conformation of the peptide was included in the system, the molecule could be seen embedding into the micelle whilst assuming the typical amphipathic disposition of the side chains.

4. Discussion

4.1. Investigation of a Set of Antimicrobial Peptides with Known Conformations

A library of 117 antimicrobial peptides (AMPs) with experimentally-known 3D structures was initially created (Table S1). The corresponding PDB entries were hierarchically clustered through the MaxCluster software [26]. The distance between two items was calculated on the root mean square deviation (RMSD), using the Kabsch rotation matrix [29,30]. The software calculates the RMSD by finding the superposition between two items which gives the lowest score. Average linkage clustering was selected over single and maximum linkage as it could be less influenced by outliers. In fact, single linkage is based on the shortest distance between any two members; maximum linkage is based instead on the largest distance between any two items; whilst average linkage adopts the average of all pairwise distances between members of the two groups which are being compared. A threshold was set at 700, aiming to obtain an acceptable number of clusters of peptides with similar folds. These provided 14 clusters, which are reported in Table 3. The centroids of the four most populated clusters were analysed in depth.

5MMK is the centroid of cluster 1, which is the most populated one, containing 24 peptides. It corresponds to the antimicrobial peptide HYL-20, whose sequence is GILSSLWKKLKKII AK-NH₂ [31]. A predominance of the basic amino acid lysine can be observed. It should be noted that Lys8 in particular is positioned next to the aromatic amino acid Trp7. 5MMK assumes an α -helix secondary structure (Figure 1b). It was observed that 19 members out of 24 in this cluster also assume at least a partial α -helix conformation (Figure 1a). Hydrophobic and hydrophilic regions of the 5MMK surfaces were calculated with Maestro (version 11.0.014, Schrödinger LLC, New York,

NY, USA) and it can be observed that the hydrophilic and hydrophobic side chains are clustered on the two opposite sides of the protein, with a predominance of the hydrophilic portion, which can be attributed to the positively-charged amino acids (Figure 1c). 5MMK therefore assumes an amphipathic configuration, as expected [32].




Figure 1. (a) Superimposition of all members of cluster 1 onto the backbone of the centroid 5MMK shown in thick blue trace representation. 19 members out of 24 in this cluster assume at least a partial α -helix conformation (thin, coloured α -carbon traces); (b) Stick representation of the experimentally-derived conformation of 5MMK. The ribbon shows how the antimicrobial peptide 5MMK assumes an α -helix conformation; (c). Side view of the PDB entry 5MMK, highlighting the polar regions of the surface. The hydrophilic part is shown in cyan, whilst the hydrophobic component is displayed in amber.

2MXQ was also investigated, being the centroid of the second most populated cluster, which includes 14 peptides (Table 3). It corresponds to DEFA1, a 34-amino-acid peptide, whose sequence is SCTCRRAWICRWGERHSGKCID9KGSTYRLCCRR [33]. DEFA1 has a rather longer sequence if compared to the first centroid analysed. However, a predominance of basic amino acid residues, in this case arginine, can still be observed, which in several cases are close to either another arginine (Arg5-Arg6, and Arg33-Arg34), or next to an aromatic amino acid, such as tryptophan, histidine or tyrosine (Arg11-Trp12, Arg15-Trp16, Tyr28-Arg29). In contrast with HYL-20, it does not assume an α -helix nor a definite conformation in solution, possibly suggesting a flexible peptide (Figure 2b) [33]. Despite this, the majority of the members belonging to cluster 2 (11 out of 14) adopt a β -sheet conformation in a part of their sequence, in clear contrast with cluster 1 previously investigated (Figure 2a). The investigation of the polarity of the surface also showed no clear predominance of one region over the other. However, a separation between the two can still be seen, with the hydrophobic portion appearing “sandwiched” between two hydrophilic areas, suggesting an amphipathic nature of the peptide (Figure 2c).

2RTV is the centroid of cluster 3, which contains 13 peptides (Table 3). It corresponds to the NMR-derived structure of the peptide Tachyplesin I in water [34]. It is a C-terminally amidated 18-residue peptide, whose sequence is KWCFRVCYRGICYRRCR-NH₂. It can be observed that it is also rich in basic amino acids, which are responsible for the overall positive charge of the peptide at neutral pH, with 5 arginine and one lysine residues. It can also be noted that these residues are always close to an aromatic residues, such as tryptophan, tyrosine or phenylalanine, with the exception of Arg15, which is however next to another Arg residue, and the terminal Arg18. 2RTV forms two β -sheets connected by a loop (Tyr8, Arg9, Gly10, Ile11) and linked together by two disulfide bridges (Cys16-Cys3 and Cys12-Cys17) (Figure 3b). The majority of the members of this cluster also assume a β -sheet conformation (Figure 3a). Although less evident than for 5MMK, here again two distinct regions can be identified: a hydrophilic portion is formed by the N-terminal Lys and C-terminal Arg and at the loop around Arg9 (Figure 3c), whilst a hydrophobic section is found around the β -sheet between Tyr8 and Trp2 (Figure 3d).




Figure 2. (a) Superimposition of all members of cluster 2 onto the backbone of the centroid 2MXQ (thick blue trace). The majority of the members of this cluster assume a partial β -sheet configuration, with only 2K35, 2MMM, 2MN5 and 2N8D including α -helix regions; (b) Stick and ribbon representations of the experimentally-derived conformation of 2MXQ which does not assume a definite conformation; (c) PDB structure 2MXQ, corresponding the defensin-like peptide DEFA1 is here shown. The hydrophilic region of the molecule surface is coloured in cyan, whilst the hydrophobic portion is shown in amber.




Figure 3. (a) Peptides populating cluster 3 superimposed onto the backbone of the centroid 2RTV (thick blue trace). No member of this cohort presented an α -helix arrangement; (b) Experimentally-derived 3D conformation of the centroid 2RTV; (c) The hydrophobic (amber) and hydrophilic (blue) regions on the surface of 2RTV are shown. It can be observed that Tachyplesin I displays a predominantly hydrophilic nature; (d) Detail of the hydrophobic region.

The peptide 2NDC is the centroid of cluster 4 which also contains 13 peptides (Table 3). Its sequence is GGLRSLGRKILRAWKKYG, which again is characterized by the presence of basic Arg and Lys residues [3]. In particular, Lys15 can be found next to aromatic Trp14 and Lys16 is next to aromatic Tyr17. It assumes a partially α -helical secondary structure, like the majority of the members of this cluster (Figure 4a,b). Unsurprisingly, its surface is also largely hydrophilic (Figure 4c). This peptide is helical in the middle of the sequence.




Figure 4. (a) Members of cluster 4 are shown superimposed to the centroid 2NDC (thick blue trace). 9 members out of 13 also assume at least a partial α -helical conformation; (b) Experimentally-derived conformation of peptide 2NDC; (c) PDB entry 2NDC with its surface investigated. Hydrophobic areas are shown in amber, hydrophilic in cyan.

Most of the NMR-derived conformations of centroids of the remaining clusters feature secondary structures observed in the first four clusters, i.e., α -helices (Figure S1b,d,h) and β -sheets (Figure S1c,f,i), while the rest adopt less ordered structures. Despite having distinct features present in the centroids of clusters 1 to 4, the members of remaining clusters do not group with those clusters due to either the presence of disulfide bonds (i.e., PDB entry 2MUH) or their larger size, which may lead to difficulty in *ab initio* prediction of their structure, as it is less reliable than the prediction of the shorter sequences [35].

4.2. Evaluation of *In Silico* Approaches to Predict Conformation of Short Cationic Peptides

All peptides with known structure and with sequence length under 15 residues were shortlisted for further analysis. Their conformations were initially predicted with the online software PEP-FOLD and then submitted to 10 ns MD simulation in an aqueous buffer. The PEP-FOLD predictions (corresponding to 0 ns conformation), as well as the conformations at 1.2 and 10 ns of the simulation were superimposed onto the experimental PDB entry in order to investigate the quality of such predictions and stability of predicted structures. It can be observed that the PEP-FOLD conformations, which correspond to the starting point of the MD simulation, are generally in good agreement with experimentally-determined structures extracted from PDB entries as suggested by RMSD values (Table 4).

The best agreement between predicted and experimental conformations was observed for the peptide corresponding to the PDB entry 2MJT, with the best superposition given by the PEP-FOLD prediction (RMSD = 0.4461 Å), which is in line with the previously observed performance of PEP-FOLD software [36]. It is not only that the backbones are aligned, but most of the side-chains too. (Figure 5, 0 ns). A similar performance was observed for other helical AMPs (2F3A, 1D7N, 2JMY, 2MAA, 1T51, 2L24, 2N9A and 2NAL), with the helical parts of the backbone aligned while the termini show flexibility (Figures S2–S9).

It is important to note that PEP-FOLD predicts the conformation of peptides in an aqueous environment. The experimental structures of 2MJT, 1G89, 2F3A, 1D7N, 2JQ2, 2JMY, 2MAA, 1D6X and 1T51 were determined in the presence of micelles, believed to induce the formation of an amphipathic surface. To establish if the predicted structures are stable in water without micelles, we have conducted MD simulations of all peptides under physiological conditions. Although the RMSD decreases over simulation time in most cases, possibly indicating a flexible peptide, most of the abovementioned peptides preserve secondary structure (Figure 5 and Figures S2–S9). This suggests that the predicted structures are stable for at least 1.2 ns of simulation despite the absence of the membrane. The PEP-FOLD predicted conformations do not fully unfold in an aqueous environment and the secondary structure is preserved during the simulation in a fully solvated system but without a membrane environment. Therefore, a short simulation of 1.2 ns without the membrane could be used to explore the dynamic nature of AMPs (Table 4).




Figure 5. The backbone superposition of PDB entry 2MJT (red) and conformations assumed at 0, 1.2 and 10 ns of MD simulation (blue).

This is particularly true for the peptide corresponding to the PDB entry 1D6X, which had 19 NMR-based conformations stored in the downloaded file. The RMSD between the lowest energy structure and the rest of the set was in the range from 1.4 to 2.25 Å, suggesting that the peptide itself is flexible in presence of micelles. Despite that flexibility, the predicted structure has key features similar to the experimental structure that are mainly preserved during simulation (Figure 6).




Figure 6. Backbone superposition of PDB entry 1D6X (red) and simulated conformations at 0, 1.2 and 10 ns (blue). No significant change was observed over the simulation time, with a slight improvement at 1.2 ns.

Similar behaviour is observed for the peptide corresponding to the PDB entry 2JQ2, for which the α -helix content was overestimated (Figure 7), as well as PDB entry 2MAA (Figure S5). It was observed that the simulation relaxed the structure into a conformation with a higher RMSD, but some of the key features became similar to the experimentally-determined conformation.

There was only one peptide in the set of the short peptides that did not have helical structure, which was extracted from the PDB entry 1G89. It assumes a “U” shape with rather flexible ends (a range of RMSD for the experimentally-determined structures was from 0.6 to 1.9 Å). The absence of the micelle and absence of intramolecular interactions due to the intrinsic nature of the peptide led to a much higher RMSD between the predicted and experimental structures (RMSD = 6.4 Å). However, it can be observed that the central part of the peptide sequence (hydrophobic and possibly responsible for driving bioactive conformation) overlaps better than the termini (Figure 8).




Figure 7. Backbone superposition of PDB entry 2JQ2 (red) and simulated conformations at 0, 1.2 and 10 ns (blue). NMR experiments show that 2JQ2 assumes relaxed coiled conformations, whilst the PEP-FOLD prediction provides a partially α -helical structure, which progressively deteriorates over the simulation time.




Figure 8. Backbone superposition of PDB entry 1G89 (red) and conformations at 0, 1.2 and 10 ns of MD simulation (blue).

These results indicate that, despite the absence of a membrane-like environment, PEP-FOLD complemented with molecular dynamics simulation of 1.2 ns can be used for predicting AMP structure and to explore the dynamics nature of these peptides, especially those that have propensity for forming an α helix.

4.3. Common Structural Features of Antimicrobial Peptides with Activity against Gram Negative Bacteria

Based on these observations, the 3D structures of 63 short cationic antimicrobial peptides with no known 3D structure were predicted by submitting the PEP-FOLD-obtained conformations to 1.2 ns MD simulation. It was chosen to only consider short peptides in anticipation of an improved pharmacokinetic profile and driving drug like properties during the design of novel molecules. The resulting conformations were once again clustered using the MaxCluster command and the resulting clusters were analysed for common features [26].

Peptide VCP-VT1 is the centroid of the most populated cluster, which contains 25 peptides (Table 5). Its sequence is FLPIIGKLLSGLL. It only contains one aromatic amino acid residue (Phe1), and one basic residue (Lys7) and it maintains an α -helical conformation after 1.2 ns MD simulation, like the majority of the members of this cluster (Figure 9a,b). All peptides in cluster 1 were also superimposed along the α -carbon atoms using the superposition tool featured in Maestro. The residues were colored according to their properties. A predominance of hydrophobic and electrostatically positively-charged residues was observed. Interestingly, a clear separation in the disposition of the two sets of residues was noted, with all the positively-charged side chains converging towards one side of the peptide (Figure 9c). This observation complies with the hypothesis that these

peptides assume an amphipathic 3D conformation [2], with a charged region responsible for binding to the negatively-charged LPS on the surface of Gram negative bacteria, and a predominantly hydrophobic nature allowing the peptide to then penetrate the membrane. The surface of the centroid VCP-VT1 was also analysed in terms of polarity, and a clear distinction between hydrophilic and hydrophobic areas could be observed (Figure 9d), in accordance with what was discussed for the peptides with experimentally-known conformations.




Figure 9. (a) Backbone superposition of all members of cluster 1 onto the centroid VCP-VT1 (thick blue trace); (b) Predicted conformation of VCP-VT1 after 1.2 ns MD simulation; (c) The peptides belonging to cluster 6 are shown superimposed and the residues are coloured according to their electrical properties: hydrophobic residues in green, positively-charged in blue, polar uncharged in cyan. A few peptides also contain negatively-charged residues (red), however the overall charge of the molecule is still positive. Two distinct areas can be observed, with a positively-charged portion and a predominant hydrophobic or uncharged region; (d) The surface of the centroid CVP-VT1 is shown along the *N*-terminal side, with hydrophobic areas in cyan and hydrophilic regions in amber. A clear distinction can be observed between the two.

Cluster 2, which contains 20 peptides, was also investigated. Its centroid is peptide UyCT1 [37], whose sequence is GFWGKLWEGVKNAI-NH₂. It is a predominantly hydrophobic peptide, with three aromatic amino acid residues (Phe2, Trp3 and Trp7) and two positively-charged residues (Lys5 and Lys11). It assumes an α -helical conformation after PEP-FOLD prediction, which is maintained during MD simulation (Figure 10b). The same can be said for the majority of the peptides forming cluster 2 (Figure 10a). The disposition of the residues was also analysed and a clear separation between hydrophobic amino acids and positively-charged residues can be observed once again (Figure 10c), in accordance with what previously observed for cluster 1 (Figure 9c). This is mirrored by the analysis of the surface of the centroid UyCT1. A clear distinction between hydrophobic and hydrophilic areas can be seen (Figure 10d), once again confirming what observed for the first set of antimicrobial peptides with experimentally-derived conformations.

The centroids of less populated clusters have less ordered structures (Figure S10), but in most cases form surfaces with amphipathic nature, those sequences can be also used as a starting point for a design of molecules with novel architectures, but the detailed analysis of structures are beyond this work.




Figure 10. (a) The members of cluster 2 are shown superimposed to the centroid UyCT1 (thick blue trace); (b) Predicted conformation of UyCT1; (c) Side view of the peptides forming cluster 2 superimposed along the α -carbon. A colour scheme was applied according to residue properties: hydrophobic residues in green, positively-charged in blue, polar uncharged in cyan and negatively-charged in red. A clear separation between the two regions can be seen (d) The surface of the centroid UyCt1 is shown along the C-terminal side, with hydrophilic areas in cyan and hydrophobic regions in amber.

4.4. MD Simulation to Evaluate Interaction of Short Antimicrobial Peptides with a Membrane-Like Structure

The use of MD simulations for the study of the behaviour of these cationic antimicrobial peptides in the presence of membrane-like structures was evaluated. With respect to this, many NMR experiments use solutions of the peptide in the presence of micelles of amphipathic molecules, whose role is to mimic the membrane. The PDB entry 2MJT, which corresponds to the NMR-derived conformation of the antimicrobial peptide Anoplin in the presence of dodecylphosphocholine (DPC) micelles, was selected as a model system to validate our molecular dynamics simulations setup [11].

Anoplin, a 12-residue C-terminally amidated peptide, has been shown to exert its antimicrobial activity through ion channel-like activity in a membrane-like environment [38]. It was shown that this system remains stable after 10 ns MD simulation, as the micelle does not disassemble and Anoplin remains embedded onto its surface, maintaining the characteristic amphipathic structure (Figure 11a–d).

The next step was to design an *in silico* system reproducing the same conditions in which the NMR experiment had been conducted [11]. The same MD protocol was therefore applied to an artificially built system, containing the micelle, the extended peptide built from scratch and the phosphate buffer. However, no interaction between the peptide and the micelle was observed at the end of the simulation, nor did the peptide seem to be able to adopt an amphipathic conformation (Figure 12).




Figure 11. (a) Initial frame of the MD simulation of the PDB entry 2MJT; (b) Anoplin embedded in the micelle at the beginning of the MD simulations; (c) Final frame of the MD simulations; (d) Anoplin remains embedded into the micelle at the end of the simulation, showing that this system is stable under the conditions used. The residues have been coloured according to their properties, with positively-charged amino acids in blue, hydrophobic in green, neutral in grey and polar uncharged in cyan. It can be observed that Anoplin maintains an amphipathic conformation throughout the simulation.



Figure 12. Conformation of extended Anoplin at the end of 10 ns MD simulation. The residues are coloured according to their properties, with electrostatically positively-charged amino acids in blue, hydrophobic in green, polar uncharged in cyan and neutral in grey. It can be observed that the peptide does not assume an amphipathic conformation as expected.

The simulation was then repeated under the same conditions but using the PEP-FOLD predicted 3D conformation of Anoplin. This time, a clear interaction between micelle and the peptide was observed, with the latter clearly embedding into the membrane-like surface after assuming an amphipathic conformation (Figure 13a–d).

This is consistent with the previously-observed inability of MD simulations to predict the correct fold from an extended structure even at time-costly simulations of 2 μ s. Those long simulations (CPU time) of even relatively small systems comprising peptide, micelle and water molecules are impractical for most academic and industrial groups mainly due to duration (real time) and available

computational resources. Therefore, having a realistic starting structure can reduce the need to predict folding of the peptide and significantly decrease the duration of simulations. Here, we have found that PEP-FOLD can predict the fold of AMP that can occur in membrane-like environments, but other methods, not tested here, can be also validated for this use, i.e., PEPstrMOD [39], simulated tempering [40], multiple simulated annealing-molecular dynamics [41] or FlexPepDock [42]. Once the methods are validated, studies can be extended to molecular dynamics simulations of a peptide in the presence of lipopolysaccharide (LPS) micelles, which could provide a more relevant representation of the interactions between the peptide and a surface of a Gram negative bacterium [43].




Figure 13. (a) Initial frame of the MD simulation on a system including the PEP-FOLD predicted 3D structure of Anoplin; (b) Initial frame of the simulation, showing the PEP-FOLD predicted conformation of Anoplin positioned 10 Å away from the surface of the micelle; (c) Final frame of the simulation; (d) Final frame of the simulation, showing Anoplin embedded into the surface of the micelle in an amphipathic conformation. Residues are coloured according to the surface, with positively-charged amino acids in blue, hydrophobic in green, polar uncharged in cyan and neutral in grey.

5. Conclusions

The structures and conformations of two sets of cationic antimicrobial peptides were clustered and compared. Importantly, the predicted conformations of AMP were in a good agreement with those determined experimentally, although the presence of a membrane was not explicitly taken into consideration. Consequently, the peptides acting against Gram negative bacteria had their conformations predicted through the online software PEP-FOLD and then submitted to molecular dynamics simulations before being clustered to identify common features possibly responsible for their activity. Significantly, the analysis of the most-populated clusters confirmed that these peptides tend to assume an amphipathic conformation, which is in accordance with their suggested mechanism of action. It was also observed that the majority of these peptides often contain basic amino acids in proximity to aromatic residues. Finally, it was demonstrated that MD simulations in combination with prediction of the initial conformation can be used to study the interaction of short AMPs with a membrane-like structure such as dodecylphosphocholine (DPC) micelles. The results of this study successfully demonstrate that a combination of *in silico* approaches can be utilized to identify common structural features of AMPs and inform the rational design of novel antimicrobial agents.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1999-4923/10/3/72/s1>, Table S1: Set of antimicrobial peptides with known 3D structures derived from NMR experiments, Table S2: Set of short sequence antimicrobial peptides, showing their size, sequence, net charge at pH 7.4 and minimum inhibitory concentration (MIC) against some of the most common Gram-negative strains, Figure S1: The experimentally-derived conformations of the PDB entries the centroids of the less populated clusters resulting from hierarchical clustering (HC) of 117 antimicrobial peptides with experimentally-known conformations, Figure S2: Backbone superposition of PDB entry 2F3A (red), with simulated conformations at 0, 1.2 and 10 ns (blue). The conformation at 1.2 ns is very similar to the PDB entry and it progressively modifies during the simulation., Figure S3: Backbone superposition of PDB entry 1D7N (red) with simulated conformations at 0, 1.2 and 10 ns (blue). Superposition slightly decreases over simulation time, suggesting a flexible peptide, especially at the extremities, Figure S4: Backbone superposition of PDB entry 2JMY (red) with simulated conformations at 0, 1.2 and 10 ns (blue). RMS at 0 and 1.2 are quite similar, but similarity decreases over simulation time, suggesting flexibility, especially at the N terminus, Figure S5: Backbone superposition of PDB entry 2MAA (red) and simulated conformations at 0, 1.2 and 10 ns (blue). RMS progressively increases during simulation time, Figure S6: Backbone superposition of PDB entry 1T51 (red) and simulated conformations at 0, 1.2 and 10 ns (blue). Similarity decreases over simulation time, with a distinct flexibility observed at the C terminus, Figure S7: Backbone superposition of PDB entry 2L24 (red) and simulated conformations at 0, 1.2 and 10 ns (blue). As opposed to the peptides analyzed previously, the NMR experiments of 2L24 were acquired in the absence of micelles. However, similarly to the previous cases, similarity also decreases over simulation time, Figure S8: Backbone superposition of PDB entry 2N9A (red) and simulated conformations at 0, 1.2 and 10 ns (blue). 2N9A NMR data were obtained in a simple solution without micelles. Similarity decreases over simulation time, Figure S9: Backbone superposition of PDB entry 2NAL (red) and simulated conformations at 0, 1.2 and 10 ns (blue). NMR data were obtained in the absence of micelles and similarity decreases over simulation time, Figure S10: The conformations centroids of the less populated clusters after hierarchical clustering of the predicted structures of cationic peptides with activity against Gram negative bacteria. References [11,12,14–16,18–22,31,33,34,37,44–173] are cited in the supplementary materials

Author Contributions: Conceptualization, M.Z, J.M. and S.R.; Methodology, M.Z. and I.P.; Formal Analysis, M.Z. and I.P.; Resources, M.Z., S.R. and J.M.; Data Curation, I.P.; Writing-Original Draft Preparation, I.P.; Writing-Review & Editing, M.Z., S.R. and J.M.; Supervision, M.Z., S.R. and J.M.

Funding: This research received no external funding.

Acknowledgments: The University of Hertfordshire and UCL School of Pharmacy are acknowledged for their support.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Wang, R.; Liu, Y.; Zhang, Q.; Jin, L.; Wang, Q.; Zhang, Y.; Wang, X.; Hu, M.; Li, L.; Qi, J.; et al. The prevalence of colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae* isolated from food animals in China: Coexistence of *mcr-1* and *bla_{NDM}* with low fitness cost. *Int. J. Antimicrob. Agents* **2018**, *51*, 739–744. [[CrossRef](#)] [[PubMed](#)]
2. Bechinger, B.; Gorr, S.U. Antimicrobial peptides: Mechanisms of action and resistance. *J. Dent. Res.* **2017**, *96*, 254–260. [[CrossRef](#)] [[PubMed](#)]
3. Kumar, P.; Kizhakkedathu, J.N.; Straus, S.K. Antimicrobial peptides: Diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules* **2018**, *8*, 4. [[CrossRef](#)] [[PubMed](#)]
4. Thevenet, P.; Shen, Y.; Maupetit, J.; Guyon, F.; Derreumaux, P.; Tuffery, P. Pep-fold: An updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. *Nucleic Acids Res.* **2012**, *40*, W288–W293. [[CrossRef](#)] [[PubMed](#)]
5. Mikut, R.; Ruden, S.; Reischl, M.; Breitling, F.; Volkmer, R.; Hilpert, K. Improving short antimicrobial peptides despite elusive rules for activity. *Biochim. Biophys. Acta* **2016**, *1858*, 1024–1033. [[CrossRef](#)] [[PubMed](#)]
6. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.; Schneider, G. Designing antimicrobial peptides: Form follows function. *Nat. Rev. Drug Discov.* **2012**, *11*, 37–51. [[CrossRef](#)] [[PubMed](#)]
7. Marquette, A.; Bechinger, B. Biophysical investigations elucidating the mechanisms of action of antimicrobial peptides and their synergism. *Biomolecules* **2018**, *8*, 18. [[CrossRef](#)] [[PubMed](#)]
8. Choi, H.; Rangarajan, N.; Weisshaar, J.C. Lights, camera, action! Antimicrobial peptide mechanisms imaged in space and time. *Trends Microbiol.* **2016**, *24*, 111–122. [[CrossRef](#)] [[PubMed](#)]
9. Wang, Y.; Zhao, T.; Wei, D.; Strandberg, E.; Ulrich, A.S.; Ulmschneider, J.P. How reliable are molecular dynamics simulations of membrane active antimicrobial peptides? *Biochim. Biophys. Acta-Biomembr.* **2014**, *1838*, 2280–2288. [[CrossRef](#)] [[PubMed](#)]

10. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank nucleic acids research. *Nucleic Acids Res.* **2000**, *28*, 235–242. [[CrossRef](#)] [[PubMed](#)]
11. Uggerhøj, L.E.; Poulsen, T.J.; Munk, J.K.; Fredborg, M.; Sondergaard, T.E.; Frimodt-Møller, N.; Hansen, P.R.; Wimmer, R. Rational design of alpha-helical antimicrobial peptides: Do's and don'ts. *ChemBiochem* **2015**, *16*, 242–253. [[CrossRef](#)] [[PubMed](#)]
12. Rozek, A.; Friedrich, C.L.; Hancock, R.E. Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. *Biochemistry* **2000**, *39*, 15765–15774. [[CrossRef](#)] [[PubMed](#)]
13. Li, X.; Li, Y.; Peterkofsky, A.; Wang, G. Nmr studies of aurein 1.2 analogs. *Biochim. Biophys. Acta* **2006**, *1758*, 1203–1214. [[CrossRef](#)] [[PubMed](#)]
14. Hori, Y.; Demura, M.; Iwadate, M.; Ulrich, A.S.; Niidome, T.; Aoyagi, H.; Asakura, T. Interaction of mastoparan with membranes studied by 1h-nmr spectroscopy in detergent micelles and by solid-state 2h-nmr and 15n-nmr spectroscopy in oriented lipid bilayers. *Eur. J. Biochem.* **2001**, *268*, 302–309. [[CrossRef](#)] [[PubMed](#)]
15. Tinoco, L.W.; Gomes-Neto, F.; Valente, A.P.; Almeida, F.C. Effect of micelle interface on the binding of anticoccidial pw2 peptide. *J. Biomol. NMR* **2007**, *39*, 315–322. [[CrossRef](#)] [[PubMed](#)]
16. Respondek, M.; Madl, T.; Gobl, C.; Golser, R.; Zangger, K. Mapping the orientation of helices in micelle-bound peptides by paramagnetic relaxation waves. *J. Am. Chem. Soc.* **2007**, *129*, 5228–5234. [[CrossRef](#)] [[PubMed](#)]
17. Saravanan, R.; Joshi, M.; Mohanram, H.; Bhunia, A.; Mangoni, M.L.; Bhattacharjya, S. NMR structure of temporin-1 Ta in lipopolysaccharide micelles: Mechanistic insight into inactivation by outer membrane. *PLoS ONE* **2013**, *8*, e72718. [[CrossRef](#)] [[PubMed](#)]
18. Schibli, D.J.; Hwang, P.M.; Vogel, H.J. Structure of the antimicrobial peptide tritrypticin bound to micelles: A distinct membrane-bound peptide fold. *Biochemistry* **1999**, *38*, 16749–16755. [[CrossRef](#)] [[PubMed](#)]
19. Lee, K.; Shin, S.Y.; Kim, K.; Lim, S.S.; Hahn, K.S.; Kim, Y. Antibiotic activity and structural analysis of the scorpion-derived antimicrobial peptide isct and its analogs. *Biochem. Biophys. Res. Commun.* **2004**, *323*, 712–719. [[CrossRef](#)] [[PubMed](#)]
20. Zhu, S.; Aumelas, A.; Gao, B. Convergent evolution-guided design of antimicrobial peptides derived from influenza a virus hemagglutinin. *J. Med. Chem.* **2011**, *54*, 1091–1095. [[CrossRef](#)] [[PubMed](#)]
21. Guerra, M.E.R.; Fadel, V.; Maltarollo, V.G.; Baldissera, G.; Honorio, K.M.; Ruggiero, J.R.; Dos Santos Cabrera, M.P. Md simulations and multivariate studies for modeling the antileishmanial activity of peptides. *Chem. Biol. Drug Dis.* **2017**, *90*, 501–510. [[CrossRef](#)] [[PubMed](#)]
22. Gunaskeker, S.; Muhammad, T.; Stromstedt, A.A.; Rosengren, K.J.; Goransson, U. Backbone-Cyclized Stable Peptide-Dimers Derived from the Human Cathelicidin ll-37 Mediate Potent Antimicrobial Activity. Available online: <https://www.rcsb.org/structure/2NA3> (accessed on 19 June 2018).
23. Wang, G.; Li, X.; Wang, Z. Apd3: The antimicrobial peptide database as a tool for research and education. *Nucleic Acids Res.* **2016**, *44*, D1087–D1093. [[CrossRef](#)] [[PubMed](#)]
24. Bowers, K.J.; Chow, E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006; p. 84.
25. Kaminski, G.A.; Friesner, R.A. Evaluation and reparametrization of the opls-aa force field for proteins via comparison with accurate quantum chemical calculations of peptides. *J. Phys. Chem. B* **2001**, *105*, 6474–6487. [[CrossRef](#)]
26. Herbert, A.; Sternberg, M. Maxcluster—A Tool for Protein Structure Comparison and Clustering. 2014. Available online: <http://www.sbg.bio.ic.ac.uk/~maxcluster/> (accessed on 19 June 2018).
27. Konno, K.; Hisada, M.; Fontana, R.; Lorenzi, C.C.B.; Naoki, H.; Itagaki, Y.; Miwa, A.; Kawai, N.; Nakata, Y.; Yashuhara, T.; et al. Anoplin, a novel antimicrobial peptide from the venom of the solitary wasp anoplius samariensis. *Biochim. Biophys. Acta* **2001**, *1550*, 70–80. [[CrossRef](#)]
28. Martinez, L.; Andrade, R.; Birgin, E.G.; Martinez, J.M. Packmol: A package for building initial configurations for molecular dynamics simulations. *J. Comput. Chem.* **2009**, *30*, 2157–2164. [[CrossRef](#)] [[PubMed](#)]
29. Kabsch, W. A solution for the best rotation to relate two sets of vectors. *Acta Crystallogr.* **1976**, *32*, 922–923. [[CrossRef](#)]

30. Kabsch, W. A discussion of the solution for the best rotation to relate two sets of vectors. *Acta Crystallogr.* **1978**, *34*, 827–828. [[CrossRef](#)]
31. Nesuta, O.; Budesinsky, M.; Hadravova, R.; Monincova, L.; Humpolickova, J.; Cerovsky, V. How proteases from enterococcus faecalis contribute to its resistance to short alpha-helical antimicrobial peptides. *Pathog. Dis.* **2017**, *75*. [[CrossRef](#)] [[PubMed](#)]
32. Hancock, R.E.W. Peptide antibiotics. *Lancet* **1997**, *349*, 418–422. [[CrossRef](#)]
33. Michalek, M.; Jung, S.; Shomali, M.R.; Cauchard, S.; Sonnichsen, F.D.; Grotzinger, J. Solution structure and functional studies of the highly potent equine antimicrobial peptide defa1. *Biochem. Biophys. Res. Commun.* **2015**, *459*, 668–672. [[CrossRef](#)] [[PubMed](#)]
34. Kushibiki, T.; Kamiya, M.; Aizawa, T.; Kumaki, Y.; Kikukawa, T.; Mizuguchi, M.; Demura, M.; Kawabata, S.; Kawano, K. Interaction between tachyplesin i, an antimicrobial peptide derived from horseshoe crab, and lipopolysaccharide. *Biochim. Biophys. Acta* **2014**, *1844*, 527–534. [[CrossRef](#)] [[PubMed](#)]
35. Beaufays, J.; Lins, L.; Thomas, A.; Brasseur, R. In silico predictions of 3d structures of linear and cyclic peptides with natural and non-proteinogenic residues. *J. Pept. Sci.* **2012**, *18*, 17–24. [[CrossRef](#)] [[PubMed](#)]
36. Amitay, M.; Goldstein, M. Evaluating the peptide structure prediction capabilities of a purely ab-initio method. *Protein Eng. Des. Sel.* **2017**, *30*, 723–727. [[CrossRef](#)] [[PubMed](#)]
37. Luna-Ramírez, K.; Quintero-Hernández, V.; Vargas-Jaimes, L.; Batista, C.V.; Winkel, K.D.; Possani, L.D. Characterization of the venom from the Australian scorpion *Urocyon yaschenkoi*: Molecular mass analysis of components, cDNA sequences and peptides with antimicrobial activity. *Toxicon* **2013**, *63*, 44–45. [[CrossRef](#)] [[PubMed](#)]
38. Dos Santos Cabrera, M.P.; Arcisio-Miranda, M.; Broggio Costa, S.T.; Konno, K.; Ruggiero, J.R.; Procopio, J.; Ruggiero Neto, J. Study of the mechanism of action of anoplín, a helical antimicrobial decapeptide with ion channel-like activity, and the role of the amidated c-terminus. *J. Pept. Sci.* **2008**, *14*, 661–669. [[CrossRef](#)] [[PubMed](#)]
39. Singh, S.; Singh, H.; Tuknait, A.; Chaudhary, K.; Singh, B.; Kumaran, S.; Raghava, G.P.S. Pepstrmod: Structure prediction of peptides containing natural, non-natural and modified residues. *Boil. Direct* **2015**, *10*, 73. [[CrossRef](#)] [[PubMed](#)]
40. Zhang, T.; Nguyen, P.H.; Nasica-Labouze, J.; Mu, Y.; Derreumaux, P. Folding atomistic proteins in explicit solvent using simulated tempering. *J. Phys. Chem. B* **2015**, *119*, 6941–6951. [[CrossRef](#)] [[PubMed](#)]
41. Hao, G.-F.; Xu, W.-F.; Yang, S.-G.; Yang, G.-F. Multiple simulated annealing-molecular dynamics (msa-md) for conformational space search of peptide and miniprotein. *Sci. Rep.* **2015**, *5*, 15568. [[CrossRef](#)] [[PubMed](#)]
42. London, N.; Raveh, B.; Cohen, E.; Fathi, G.; Schueler-Furman, O. Rosetta flexpepdock web server—high resolution modeling of peptide-protein interactions. *Nucleic Acids Res.* **2011**, *39*, W249–W253. [[CrossRef](#)] [[PubMed](#)]
43. Beveridge, T.J. Structures of gram-negative cell walls and their derived membrane vesicles. *J. Bacteriol.* **1999**, *181*, 4725–4733. [[PubMed](#)]
44. Dubovskii, P.V.; Vassilevski, A.A.; Samsonova, O.V.; Egorova, N.S.; Kozlov, S.A.; Feofanov, A.V.; Arseniev, A.S.; Grishin, E.V. Novel lynx spider toxin shares common molecular architecture with defense peptides from frog skin. *FEBS J.* **2011**, *278*, 4382–4393. [[CrossRef](#)] [[PubMed](#)]
45. Pillong, M.; Hiss, J.A.; Schneider, P.; Lin, Y.C.; Posselt, G.; Pfeiffer, B.; Blatter, M.; Müller, A.T.; Bachler, S.; Neuhaus, C.S.; et al. Rational design of membrane-pore-forming peptides. *Small* **2017**, *13*. [[CrossRef](#)] [[PubMed](#)]
46. Usachev, K.S.; Kolosova, O.A.; Klochkova, E.A.; Yulmetov, A.R.; Aganov, A.V.; Klochkov, V.V. Oligomerization of the antimicrobial peptide protegrin-5 in a membrane-mimicking environment. Structural studies by high-resolution NMR spectroscopy. *Eur. Biophys. J.* **2017**, *46*, 293–300. [[CrossRef](#)] [[PubMed](#)]
47. Pal, I.; Atreya, H.S.; Bhunia, A. Antimicrobial Peptide Andersonin-y1 (ay1). Available online: <http://www.rcsb.org/structure/5YKK> (accessed on 14 May 2018).
48. Herrera, A.; Xiao, Y.; Soulages, J.L.; Bommineni, Y.R.; Prakash, O.; Zhang, G. The Central Kink Region of Alpha-Helical Fowlicidin-2 Is Critically Involved in Antibacterial and Lipopolysaccharide-Neutralizing Activities. Available online: <http://www.rcsb.org/structure/2GDL> (accessed on 14 May 2018).
49. Bommineni, Y.R.; Dai, H.; Gong, Y.X.; Soulages, J.L.; Fernando, S.C.; Desilva, U.; Prakash, O.; Zhang, G. Fowlicidin-3 is an alpha-helical cationic host defense peptide with potent antibacterial and lipopolysaccharide-neutralizing activities. *FEBS J.* **2007**, *274*, 418–428. [[CrossRef](#)] [[PubMed](#)]

50. Vassilevski, A.A.; Musolyamov, A.; Nikonorova, A.; Finikina, E.; Slavokhotova, A.; Shagin, D.; Bozin, T.N.; BOcharov, E.V.; Ovchinnikova, T.; Arseniev, A.A.; et al. Common Chickweed (*Stellaria Media*) Antifungal Peptides with Chitin-Binding Domain Provide Unique Plant Defense Strategy. Available online: <http://www.rcsb.org/structure/2KUS> (accessed on 14 May 2018).
51. Shenkarev, Z.O.; Panteleev, P.V.; Balandin, S.V.; Gizatullina, A.K.; Altukhov, D.A.; Finkina, E.I.; Kokryakov, V.N.; Arseniev, A.S.; Ovchinnikova, T.V. Recombinant expression and solution structure of antimicrobial peptide aurelin from jellyfish aurelia aurita. *Biochem. Biophys. Res. Commun.* **2012**, *429*, 63–69. [[CrossRef](#)] [[PubMed](#)]
52. Wommack, A.J.; Robson, S.A.; Wanniarachchi, Y.A.; Wan, A.; Turner, C.J.; Wagner, G.; Nolan, E.M. Nmr solution structure and condition-dependent oligomerization of the antimicrobial peptide human defensin 5. *Biochemistry* **2012**, *51*, 9624–9637. [[CrossRef](#)] [[PubMed](#)]
53. Conibear, A.C.; Rosengren, K.J.; Daly, N.L.; Henriques, S.T.; Craik, D.J. The cyclic cystine ladder in theta-defensins is important for structure and stability, but not antibacterial activity. *J. Boil. Chem.* **2013**, *288*, 10830–10840. [[CrossRef](#)] [[PubMed](#)]
54. Ovchinnikov, K.V.; Kristiansen, P.E.; Uzelac, G.; Topisirovic, L.; Kojic, M.; Nissen-Meyer, J.; Nes, I.F.; Diep, D.B. Defining the structure and receptor binding domain of the leaderless bacteriocin lsbb. *J. Boil. Chem.* **2014**, *289*, 23838–23845. [[CrossRef](#)] [[PubMed](#)]
55. Lee, J.T.; Wang, G.; Tam, Y.T.; Tam, C. Membrane-active epithelial keratin 6a fragments (kamps) are unique human antimicrobial peptides with a non-alpha-beta structure. *Front. Microbiol.* **2016**, *7*, 1799. [[CrossRef](#)] [[PubMed](#)]
56. Mandard, N.; Bulet, P.; Caille, A.; Daffre, S.; Vovelle, F. The solution structure of gomesin, an antimicrobial cysteine-rich peptide from the spider. *Eur. J. Biochem.* **2002**, *269*, 1190–1198. [[CrossRef](#)] [[PubMed](#)]
57. Bourbigot, S.; Dodd, E.; Horwood, C.; Cumby, N.; Fardy, L.; Welch, W.H.; Ramjan, Z.; Sharma, S.; Waring, A.J.; Yeaman, M.R.; et al. Antimicrobial peptide rp-1 structure and interactions with anionic versus zwitterionic micelles. *Biopolymers* **2009**, *91*, 1–13. [[CrossRef](#)] [[PubMed](#)]
58. Dubovskii, P.V.; Volynsky, P.E.; Polyansky, A.A.; Karpunin, D.V.; Chupin, V.V.; Efremov, R.G.; Arseniev, A.S. Three-dimensional structure/hydrophobicity of laticins specifies their mode of membrane activity. *Biochemistry* **2008**, *47*, 3525–3533. [[CrossRef](#)] [[PubMed](#)]
59. Petit, V.W.; Rolland, J.L.; Blond, A.; Cazevieille, C.; Djediat, C.; Peduzzi, J.; Goulard, C.; Bachere, E.; Dupont, J.; Destoumieux-Garzon, D.; et al. A hemocyanin-derived antimicrobial peptide from the penaeid shrimp adopts an alpha-helical structure that specifically permeabilizes fungal membranes. *Biochim. Biophys. Acta* **2016**, *1860*, 557–568. [[CrossRef](#)] [[PubMed](#)]
60. Aboye, T.L.; Stromstedt, A.A.; Gunasekera, S.; Bruhn, J.G.; El-Seedi, H.; Rosengren, K.J.; Goransson, U. A cactus-derived toxin-like cystine knot peptide with selective antimicrobial activity. *Chembiochem* **2015**, *16*, 1068–1077. [[CrossRef](#)] [[PubMed](#)]
61. Berkut, A.A.; Usmanova, D.R.; Peigneur, S.; Oparin, P.B.; Mineev, K.S.; Odintsova, T.I.; Tytgat, J.; Arseniev, A.S.; Grishin, E.V.; Vassilevski, A.A. Structural similarity between defense peptide from wheat and scorpion neurotoxin permits rational functional design. *J. Boil. Chem.* **2014**, *289*, 14331–14340. [[CrossRef](#)] [[PubMed](#)]
62. Subasinghage, A.P.; O'Flynn, D.; Conlon, J.M.; Hewage, C.M. Conformational and membrane interaction studies of the antimicrobial peptide alyteserin-1c and its analogue [e4k]alyteserin-1c. *Biochim. Biophys. Acta* **2011**, *1808*, 1975–1984. [[CrossRef](#)] [[PubMed](#)]
63. Henriques, S.T.; Tan, C.; Craik, D.J.; Clark, R.J. Structural and Functional Analysis of Human Liver-Expressed Antimicrobial Peptide 2. Available online: <http://www.rcsb.org/structure/2L1Q> (accessed on 19 June 2018).
64. Silva, F.D.; Rezende, C.A.; Rossi, D.C.; Esteves, E.; Dyszy, F.H.; Schreier, S.; Gueiros-Filho, F.; Campos, C.B.; Pires, J.R.; Daffre, S. Structure and mode of action of microplusin, a copper ii-chelating antimicrobial peptide from the cattle tick rhipicephalus (boophilus) microplus. *J. Boil. Chem.* **2009**, *284*, 34735–34746. [[CrossRef](#)] [[PubMed](#)]
65. Ovchinnikova, T.V.; Shenkarev, Z.O.; Nadezhdin, K.D.; Balandin, S.V.; Zhmak, M.N.; Kudelina, I.A.; Finkina, E.I.; Kokryakov, V.N.; Arseniev, A.S. Recombinant expression, synthesis, purification, and solution structure of arenicin. *Biochem. Biophys. Res. Commun.* **2007**, *360*, 156–162. [[CrossRef](#)] [[PubMed](#)]

66. Hilge, M.; Gloor, S.M.; Rypniewski, W.; Sauer, O.; Heightman, T.D.; Zimmermann, W.; Winterhalter, K.; Piontek, K. High-resolution native and complex structures of thermostable beta-mannanase from thermomonospora fusca—Substrate specificity in glycosyl hydrolase family 5. *Structure* **1998**, *6*, 1433–1444. [[CrossRef](#)]
67. Rosenzweig, A.C.; Frederick, C.A.; Lippard, S.J.; Nordlund, P. Crystal structure of a bacterial non-haem iron hydroxylase that catalyses the biological oxidation of methane. *Nature* **1993**, *366*, 537–543. [[CrossRef](#)] [[PubMed](#)]
68. Tack, B.F.; Sawai, M.V.; Kearney, W.R.; Robertson, A.D.; Sherman, M.A.; Wang, W.; Hong, T.; Boo, L.M.; Wu, H.; Waring, A.J.; et al. Smap-29 has two lps-binding sites and a central hinge. *Eur. J. Biochem.* **2002**, *269*, 1181–1189. [[CrossRef](#)] [[PubMed](#)]
69. Brunhuber, N.M.; Thoden, J.B.; Blanchard, J.S.; Vanhooke, J.L. Rhodococcus l-phenylalanine dehydrogenase: Kinetics, mechanism, and structural basis for catalytic specificity. *Biochemistry* **2000**, *39*, 9174–9187. [[CrossRef](#)] [[PubMed](#)]
70. Panteleev, P.V.; Myshkin, M.Y.; Shenkarev, Z.O.; Ovchinnikova, T.V. Dimerization of the antimicrobial peptide arenicin plays a key role in the cytotoxicity but not in the antibacterial activity. *Biochem. Biophys. Res. Commun.* **2017**, *482*, 1320–1326. [[CrossRef](#)] [[PubMed](#)]
71. Pal, I.; Atreya, H.S.; Bhunia, A. Antimicrobial Peptide ay1c Designed from the Skin Secretion of Chinese Odorous Frogs. Available online: <http://www.rcsb.org/structure/5YKL> (accessed on 14 May 2018).
72. Wang, G.; Elliott, M.; Cogen, A.L.; Ezell, E.L.; Gallo, R.L.; Hancock, R.E. Structure, dynamics, and antimicrobial and immune modulatory activities of human ll-23 and its single-residue variants mutated on the basis of homologous primate cathelicidins. *Biochemistry* **2012**, *51*, 653–664. [[CrossRef](#)] [[PubMed](#)]
73. Uteng, M.; Hauge, H.H.; Markwick, P.R.; Fimland, G.; Mantzilas, D.; Nissen-Meyer, J.; Muhle-Goll, C. Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide sakacin p and a sakacin p variant that is structurally stabilized by an inserted c-terminal disulfide bridge. *Biochemistry* **2003**, *42*, 11417–11426. [[CrossRef](#)] [[PubMed](#)]
74. Sprules, T.; Kawulka, K.E.; Gibbs, A.C.; Wishart, D.S.; Vederas, J.C. Nmr solution structure of the precursor for carnobacteriocin b2, an antimicrobial peptide from carnobacterium piscicola. *Eur. J. Biochem.* **2004**, *271*, 1748–1756. [[CrossRef](#)] [[PubMed](#)]
75. Andra, J.; Jakovkin, I.; Grotzinger, J.; Hecht, O.; Krasnosdembskaya, A.D.; Goldmann, T.; Gutschmann, T.; Leippe, M. Structure and mode of action of the antimicrobial peptide arenicin. *Biochem. J.* **2008**, *410*, 113–122. [[CrossRef](#)] [[PubMed](#)]
76. Campagna, S.; Saint, N.; Molle, G.; Aumelas, A. Structure and mechanism of action of the antimicrobial peptide piscidin. *Biochemistry* **2007**, *46*, 1771–1778. [[CrossRef](#)] [[PubMed](#)]
77. Tseng, T.S.; Chen, C. Solution Structure of a Novel Antimicrobial Peptide, p1, from Jumper Ant Myrmecia Pilosula. Available online: <http://www.rcsb.org/structure/5X3L> (accessed on 19 June 2018).
78. Nolde, S.B.; Vassilevski, A.A.; Rogozhin, E.A.; Barinov, N.A.; Balashova, T.A.; Samsonova, O.V.; Baranov, Y.V.; Feofanov, A.V.; Egorov, T.A.; Arseniev, A.S.; et al. Disulfide-stabilized helical hairpin structure and activity of a novel antifungal peptide ecamp1 from seeds of barnyard grass (echinochloa crus-galli). *J. Boil. Chem.* **2011**, *286*, 25145–25153. [[CrossRef](#)] [[PubMed](#)]
79. Bhunia, A.; Ramamoorthy, A.; Bhattacharjya, S. Helical hairpin structure of a potent antimicrobial peptide msi-594 in lipopolysaccharide micelles by nmr spectroscopy. *Chemistry* **2009**, *15*, 2036–2040. [[CrossRef](#)] [[PubMed](#)]
80. Dubovskii, P.V.; Volynsky, P.E.; Polyansky, A.A.; Chupin, V.V.; Efremov, R.G.; Arseniev, A.S. Spatial structure and activity mechanism of a novel spider antimicrobial peptide. *Biochemistry* **2006**, *45*, 10759–10767. [[CrossRef](#)] [[PubMed](#)]
81. Chi, S.W.; Kim, J.S.; Kim, D.H.; Lee, S.H.; Park, Y.H.; Han, K.H. Solution structure and membrane interaction mode of an antimicrobial peptide gaegurin 4. *Biochem. Biophys. Res. Commun.* **2007**, *352*, 592–597. [[CrossRef](#)] [[PubMed](#)]
82. Shalev, D.E.; Rotem, S.; Fish, A.; Mor, A. Consequences of n-acylation on structure and membrane binding properties of dermaseptin derivative k4-s4-(1-13). *J. Boil. Chem.* **2006**, *281*, 9432–9438. [[CrossRef](#)] [[PubMed](#)]
83. Fujitani, N.; Kouno, T.; Nakahara, T.; Takaya, K.; Osaki, T.; Kawabata, S.; Mizuguchi, M.; Aizawa, T.; Demura, M.; Nishimura, S.; et al. The solution structure of horseshoe crab antimicrobial peptide tachystatin b with an inhibitory cystine-knot motif. *J. Pept. Sci.* **2007**, *13*, 269–279. [[CrossRef](#)] [[PubMed](#)]

84. Agadi, N.; Kumar, A. Structure, Function and Membrane Interaction Studies of Two Synthetic Antimicrobial Peptides Using Solution and Solid State nmr. (2ndc). Available online: <https://www.rcsb.org/structure/2ndc> (accessed on 14 May 2018).
85. Li, X.; Li, Y.; Han, H.; Miller, D.W.; Wang, G. Solution structures of human Ii-37 fragments and nmr-based identification of a minimal membrane-targeting antimicrobial and anticancer region. *J. Am. Chem. Soc.* **2006**, *128*, 5776–5785. [[CrossRef](#)] [[PubMed](#)]
86. Godreuil, S.; Leban, N.; Padilla, A.; Hamel, R.; Luplertlop, N.; Chauffour, A.; Vittecoq, M.; Hoh, F.; Thomas, F.; Sougakoff, W.; et al. Aedesin: Structure and antimicrobial activity against multidrug resistant bacterial strains. *PLoS ONE* **2014**, *9*, e105441. [[CrossRef](#)] [[PubMed](#)]
87. Sawai, M.V.; Waring, A.J.; Kearney, W.R.; McCray, P.B., Jr.; Forsyth, W.R.; Lehrer, R.I.; Tack, B.F. Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides. *Protein Eng.* **2002**, *15*, 225–232. [[CrossRef](#)] [[PubMed](#)]
88. Powers, J.P.; Rozek, A.; Hancock, R.E. Structure-activity relationships for the beta-hairpin cationic antimicrobial peptide polyphemusin i. *Biochim. Biophys. Acta* **2004**, *1698*, 239–250. [[CrossRef](#)] [[PubMed](#)]
89. Yang, Y.; Poncet, J.; Garnier, J.; Zatylny, C.; Bachere, E.; Aumelas, A. Solution structure of the recombinant penaeidin-3, a shrimp antimicrobial peptide. *J. Boil. Chem.* **2003**, *278*, 36859–36867. [[CrossRef](#)] [[PubMed](#)]
90. Kristiansen, P.E.; Fimland, G.; Mantzilas, D.; Nissen-Meyer, J. Structure and mode of action of the membrane-permeabilizing antimicrobial peptide pheromone plantaricin a. *J. Boil. Chem.* **2005**, *280*, 22945–22950. [[CrossRef](#)] [[PubMed](#)]
91. Syvitski, R.T.; Burton, I.; Mattatall, N.R.; Douglas, S.E.; Jakeman, D.L. Structural characterization of the antimicrobial peptide pleurocidin from winter flounder. *Biochemistry* **2005**, *44*, 7282–7293. [[CrossRef](#)] [[PubMed](#)]
92. Haugen, H.S.; Fimland, G.; Nissen-Meyer, J.; Kristiansen, P.E. Three-dimensional structure in lipid micelles of the pediocin-like antimicrobial peptide curvacin a. *Biochemistry* **2005**, *44*, 16149–16157. [[CrossRef](#)] [[PubMed](#)]
93. Baek, M.; Kamiya, M.; Kushibiki, T.; Nakazumi, T.; Tomisawa, S.; Abe, C.; Kumaki, Y.; Kikukawa, T.; Demura, M.; Kawano, K.; et al. Lipopolysaccharide Bound Structure of Antimicrobial Peptide Cecropin p1 by Nmr Spectroscopy. Available online: <http://www.rcsb.org/structure/2N92> (accessed on 14 May 2018).
94. Hunter, H.N.; Fulton, D.B.; Ganz, T.; Vogel, H.J. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. *J. Boil. Chem.* **2002**, *277*, 37597–37603. [[CrossRef](#)] [[PubMed](#)]
95. Logashina, Y.A.; Solstad, R.G.; Mineev, K.S.; Korolkova, Y.V.; Mosharova, I.V.; Dyachenko, I.A.; Palikov, V.A.; Palikova, Y.A.; Murashev, A.N.; Arseniev, A.S.; et al. New disulfide-stabilized fold provides sea anemone peptide to exhibit both antimicrobial and trpa1 potentiating properties. *Toxins* **2017**, *9*, 154. [[CrossRef](#)] [[PubMed](#)]
96. Maksimov, M.O.; Pelczer, I.; Link, A.J. Precursor-centric genome-mining approach for lasso peptide discovery. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 15223–15228. [[CrossRef](#)] [[PubMed](#)]
97. Datta, A.; Kundu, P.; Bhunia, A. Designing potent antimicrobial peptides by disulphide linked dimerization and n-terminal lipidation to increase antimicrobial activity and membrane perturbation: Structural insights into lipopolysaccharide binding. *J. Colloid Interface Sci.* **2016**, *461*, 335–345. [[CrossRef](#)] [[PubMed](#)]
98. Suetake, T.; Tsuda, S.; Kawabata, S.; Miura, K.; Iwanaga, S.; Hikichi, K.; Nitta, K.; Kawano, K. Chitin-binding proteins in invertebrates and plants comprise a common chitin-binding structural motif. *J. Boil. Chem.* **2000**, *275*, 17929–17932. [[CrossRef](#)] [[PubMed](#)]
99. Monincova, L.; Budesinsky, M.; Cujova, S.; Cerovsky, V.; Veverka, V. Structural basis for antimicrobial activity of lasiopepsin. *Chembiochem* **2014**, *15*, 301–308. [[CrossRef](#)] [[PubMed](#)]
100. Jordan, J.B.; Poppe, L.; Haniu, M.; Arvedson, T.; Syed, R.; Li, V.; Kohno, H.; Kim, H.; Schnier, P.D.; Harvey, T.S.; et al. Hepcidin revisited, disulfide connectivity, dynamics, and structure. *J. Boil. Chem.* **2009**, *284*, 24155–24167. [[CrossRef](#)] [[PubMed](#)]
101. Mohanram, H. NMR structure of temporin-1 Ta in lipopolysaccharide micelles: Mechanistic insight into inactivation by outer membrane. Available online: <http://www.rcsb.org/structure/2MAA> (accessed on 19 June 2018).
102. Yang, S.; Jung, H.; Kim, J. Solution Structure of Bmap-27. Available online: <http://www.rcsb.org/structure/2KET> (accessed on 14 May 2018).

103. Agadi, N.; Kumar, A. Structure, Function and Membrane Interaction Studies of Two SYNTHETIC Antimicrobial Peptides Using Solution and Solid State Nmr. (2nde). Available online: <http://www.rcsb.org/structure/2NDE> (accessed on 14 May 2018).
104. Powers, J.P.; Tan, A.; Ramamoorthy, A.; Hancock, R.E. Solution structure and interaction of the antimicrobial polyphemusins with lipid membranes. *Biochemistry* **2005**, *44*, 15504–15513. [[CrossRef](#)] [[PubMed](#)]
105. Laederach, A.; Andreotti, A.H.; Fulton, D.B. Solution and micelle-bound structures of tachyplesin i and its active aromatic linear derivatives. *Biochemistry* **2002**, *41*, 12359–12368. [[CrossRef](#)] [[PubMed](#)]
106. Sit, C.S.; McKay, R.T.; Hill, C.; Ross, R.P.; Vederas, J.C. The 3d structure of thuricin cd, a two-component bacteriocin with cysteine sulfur to alpha-carbon cross-links. *J. Am. Chem. Soc.* **2011**, *133*, 7680–7683. [[CrossRef](#)] [[PubMed](#)]
107. Mineev, K.S.; Berkut, A.A.; Novikova, R.V.; Oparin, P.B.; Grishin, E.V.; Arseniev, A.S.; Vassilevski, A.A. Nmr Spatial Structure of Tk-Hefu Peptide. Available online: <http://www.rcsb.org/structure/5LM0> (accessed on 16 May 2018).
108. Metelev, M.; Arseniev, A.; Bushin, L.B.; Kuznedelov, K.; Artamonova, T.O.; Kondratenko, R.; Khodorkovskii, M.; Seyedsayamdost, M.R.; Severinov, K. Acinetodin and klebsidin, rna polymerase targeting lasso peptides produced by human isolates of acinetobacter gyllenbergii and klebsiella pneumoniae. *ACS Chem. Boil.* **2017**, *12*, 814–824. [[CrossRef](#)] [[PubMed](#)]
109. Li, Y.; Ducasse, R.; Blond, A.; Zirah, S.; Goulard, C.; Lescop, E.; Guittet, E.; Pernodet, J.; Rebuffat, S. Structure and Biosynthesis of Svceucin, an Antibacterial Type i Lasso Peptide from Streptomyces Svceus. Available online: <http://www.rcsb.org/structure/2LS1> (accessed on 16 May 2018).
110. Rogne, P.; Fimland, G.; Nissen-Meyer, J.; Kristiansen, P.E. Three-dimensional structure of the two peptides that constitute the two-peptide bacteriocin lactococcin g. *Biochim. Biophys. Acta* **2008**, *1784*, 543–554. [[CrossRef](#)] [[PubMed](#)]
111. Mandard, N.; Sy, D.; Maufrais, C.; Bonmatin, J.M.; Bulet, P.; Hetru, C.; Vovelle, F. Androctonin, a novel antimicrobial peptide from scorpion androctonus australis: Solution structure and molecular dynamics simulations in the presence of a lipid monolayer. *J. Biomol. Struct. Dyn.* **1999**, *17*, 367–380. [[CrossRef](#)] [[PubMed](#)]
112. Hwang, P.M.; Zhou, N.; Shan, X.; Arrowsmith, C.H.; Vogel, H.J. Three-dimensional solution structure of lactoferricin b, an antimicrobial peptide derived from bovine lactoferrin. *Biochemistry* **1998**, *37*, 4288–4298. [[CrossRef](#)] [[PubMed](#)]
113. Datta, A.; Bhattacharyya, D.; Singh, S.; Ghosh, A.; Schmidtchen, A.; Malmsten, M.; Bhunia, A. Role of aromatic amino acids in lipopolysaccharide and membrane interactions of antimicrobial peptides for use in plant disease control. *J. Boil. Chem.* **2016**, *291*, 13301–13317. [[CrossRef](#)] [[PubMed](#)]
114. Usachev, K.S.; Efimov, S.V.; Kolosova, O.A.; Klochkova, E.A.; Aganov, A.V.; Klochkov, V.V. Antimicrobial peptide protegrin-3 adopt an antiparallel dimer in the presence of dpc micelles: A high-resolution nmr study. *J. Biomol. NMR* **2015**, *62*, 71–79. [[CrossRef](#)] [[PubMed](#)]
115. Usachev, K.S.; Efimov, S.V.; Kolosova, O.A.; Filippov, A.V.; Klochkov, V.V. High-resolution nmr structure of the antimicrobial peptide protegrin-2 in the presence of dpc micelles. *J. Biomol. NMR* **2015**, *61*, 227–234. [[CrossRef](#)] [[PubMed](#)]
116. Fahrner, R.L.; Dieckmann, T.; Harwig, S.S.; Lehrer, R.I.; Eisenberg, D.; Feigon, J. Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. *Chem. Boil.* **1996**, *3*, 543–550. [[CrossRef](#)]
117. Lohans, C.T.; Towle, K.M.; Miskolzie, M.; McKay, R.T.; van Belkum, M.J.; McMullen, L.M.; Vederas, J.C. Solution structures of the linear leaderless bacteriocins enterocin 7a and 7b resemble carnocyclin a, a circular antimicrobial peptide. *Biochemistry* **2013**, *52*, 3987–3994. [[CrossRef](#)] [[PubMed](#)]
118. Bhunia, A.; Domadia, P.N.; Torres, J.; Hallock, K.J.; Ramamoorthy, A.; Bhattacharjya, S. Nmr structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: Mechanism of outer membrane permeabilization. *J. Boil. Chem.* **2010**, *285*, 3883–3895. [[CrossRef](#)] [[PubMed](#)]
119. Landon, C.; Meudal, H.; Boulanger, N.; Bulet, P.; Vovelle, F. Solution structures of stomoxyn and spinigerin, two insect antimicrobial peptides with an alpha-helical conformation. *Biopolymers* **2006**, *81*, 92–103. [[CrossRef](#)] [[PubMed](#)]

120. Wei, S.; Liao, Y.; Chen, C. Solution Structure of Tilapia Piscidin 4, an Antimicrobial Peptide Effective against Multidrug Resistant Helicobacter Pylori. Available online: <http://www.rcsb.org/structure/5H2S> (accessed on 16 May 2018).
121. Jung, S.; Dingley, A.J.; Augustin, R.; Anton-Erxleben, F.; Stanisak, M.; Gelhaus, C.; Gutschmann, T.; Hammer, M.U.; Podschun, R.; Bonvin, A.M.; et al. Hydramacin-1, structure and antibacterial activity of a protein from the basal metazoan hydra. *J. Boil. Chem.* **2009**, *284*, 1896–1905. [[CrossRef](#)] [[PubMed](#)]
122. Mygind, P.H.; Fischer, R.L.; Schnorr, K.M.; Hansen, M.T.; Sonksen, C.P.; Ludvigsen, S.; Raventos, D.; Buskov, S.; Christensen, B.; De Maria, L.; et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. *Nature* **2005**, *437*, 975–980. [[CrossRef](#)] [[PubMed](#)]
123. Rogne, P.; Haugen, C.; Fimland, G.; Nissen-Meyer, J.; Kristiansen, P.E. Three-dimensional structure of the two-peptide bacteriocin plantaricin jk. *Peptides* **2009**, *30*, 1613–1621. [[CrossRef](#)] [[PubMed](#)]
124. Japelj, B.; Zorko, M.; Majerle, A.; Pristovsek, P.; Sanchez-Gomez, S.; Martinez de Tejada, G.; Moriyon, I.; Blondelle, S.E.; Brandenburg, K.; Andra, J.; et al. The acyl group as the central element of the structural organization of antimicrobial lipopeptide. *J. Am. Chem. Soc.* **2007**, *129*, 1022–1023. [[CrossRef](#)] [[PubMed](#)]
125. Resende, J.M.; Moraes, C.M.; Prates, M.V.; Cesar, A.; Almeida, F.C.; Mundim, N.C.; Valente, A.P.; Bemquerer, M.P.; Pilo-Veloso, D.; Bechinger, B. Solution nmr structures of the antimicrobial peptides phylloseptin-1, -2, and -3 and biological activity: The role of charges and hydrogen bonding interactions in stabilizing helix conformations. *Peptides* **2008**, *29*, 1633–1644. [[CrossRef](#)] [[PubMed](#)]
126. Wang, G.; Eband, R.F.; Mishra, B.; Lushnikova, T.; Thomas, V.C.; Bayles, K.W.; Eband, R.M. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin ll-37. *Antimicrob. Agents Chemother.* **2012**, *56*, 845–856. [[CrossRef](#)] [[PubMed](#)]
127. Martins, J.C.; Maes, D.; Loris, R.; Pepermans, H.A.; Wyns, L.; Willem, R.; Verheyden, P. H nmr study of the solution structure of ac-amp2, a sugar binding antimicrobial protein isolated from *amaranthus caudatus*. *J. Mol. Biol.* **1996**, *258*, 322–333. [[CrossRef](#)]
128. Oh, D.; Shin, S.Y.; Lee, S.; Kang, J.H.; Kim, S.D.; Ryu, P.D.; Hahm, K.S.; Kim, Y. Role of the hinge region and the tryptophan residue in the synthetic antimicrobial peptides, cecropin a(1-8)-magainin 2(1-12) and its analogues, on their antibiotic activities and structures. *Biochemistry* **2000**, *39*, 11855–11864. [[CrossRef](#)] [[PubMed](#)]
129. Kim, J.K.; Lee, E.; Shin, S.; Jeong, K.W.; Lee, J.Y.; Bae, S.H.; Kim, S.H.; Lee, J.; Kim, S.R.; Lee, D.G.; et al. Structure and Function of Papiliocin with Antimicrobial and Anti-Inflammatory Activities Isolated from the Swallowtail Butterfly, *Papilio Xuthus*. Available online: <http://www.rcsb.org/structure/2LA2> (accessed on 16 May 2018).
130. Santana, M.J.; de Oliveira, A.L.; Queiroz Junior, L.H.; Mandal, S.M.; Matos, C.O.; Dias Rde, O.; Franco, O.L.; Liao, L.M. Structural insights into cn-amp1, a short disulfide-free multifunctional peptide from green coconut water. *FEBS Lett.* **2015**, *589*, 639–644. [[CrossRef](#)] [[PubMed](#)]
131. Essig, A.; Hofmann, D.; Munch, D.; Gayathri, S.; Kunzler, M.; Kallio, P.T.; Sahl, H.G.; Wider, G.; Schneider, T.; Aebi, M. Copsin, a novel peptide-based fungal antibiotic interfering with the peptidoglycan synthesis. *J. Boil. Chem.* **2014**, *289*, 34953–34964. [[CrossRef](#)] [[PubMed](#)]
132. Falcao, C.B.; Perez-Peinado, C.; de la Torre, B.G.; Mayol, X.; Zamora-Carreras, H.; Jimenez, M.A.; Radis-Baptista, G.; Andreu, D. Structural dissection of crotalicidin, a rattlesnake venom cathelicidin, retrieves a fragment with antimicrobial and antitumor activity. *J. Med. Chem.* **2015**, *58*, 8553–8563. [[CrossRef](#)] [[PubMed](#)]
133. Fontana, R.; Mendes, M.A.; de Souza, B.M.; Konno, K.; Cesar, L.M.; Malaspina, O.; Palma, M.S. Jelleines: A family of antimicrobial peptides from the royal jelly of honeybees (*apis mellifera*). *Peptides* **2004**, *25*, 919–928. [[CrossRef](#)] [[PubMed](#)]
134. Mandal, S.M.; Dey, S.; Mandal, M.; Sarkar, S.; Maria-Neto, S.; Franco, O.L. Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. *Peptides* **2009**, *30*, 633–637. [[CrossRef](#)] [[PubMed](#)]
135. Sung, W.S.; Park, S.H.; Lee, D.G. Antimicrobial effect and membrane-active mechanism of urecjistachykinins, neuropeptides derived from *urechis uncinatus*. *FEBS Lett.* **2008**, *582*, 2463–2466. [[CrossRef](#)] [[PubMed](#)]
136. Hou, F.; Li, J.; Pan, P.; Xu, J.; Liu, L.; Liu, W.; Song, B.; Li, N.; Wan, J.; Gao, H. Isolation and characterization of a new antimicrobial peptide from the skin of *xenopus laevis*. *Int. J. Antimicrob. Agents* **2011**, *36*, 510–515. [[CrossRef](#)] [[PubMed](#)]

137. Wang, M.; Wang, Y.; Wang, A.; Song, Y.; Ma, D.; Yang, H.; Ma, Y.; Lai, R. Five novel antimicrobial peptides from skin secretions of the frog, *amolops loloensis*. *Comp. Biochem. Physiol. Part B Biochem. Mol. Boil.* **2010**, *155*, 72–76. [[CrossRef](#)] [[PubMed](#)]
138. Ge, L.; Chen, X.; Ma, C.; Zhou, M.; Xi, X.; Wang, L.; Ding, A.; Duan, J.; Chen, T.; Shaw, C. Balteatide: A novel antimicrobial decapeptide from the skin secretion of the purple-sided leaf frog, *phyllomedusa baltea*. *Sci. World J.* **2014**, *2014*. [[CrossRef](#)] [[PubMed](#)]
139. Kang, S.J.; Won, H.S.; Choi, W.S.; Lee, B.J. De novo generation of antimicrobial 1k peptides with a single tryptophan at the critical amphipathic interface. *J. Pept. Sci.* **2009**, *15*, 583–588. [[CrossRef](#)] [[PubMed](#)]
140. Sai, K.P.; Jagannadham, M.V.; Vairamani, M.; Raju, N.P.; Devi, A.S.; Nagaraj, R.; Sitaram, N. Tigerinins: Novel antimicrobial peptides from the indian frog *rana tigerina*. *J. Boil. Chem.* **2001**, *276*, 2701–2707. [[CrossRef](#)] [[PubMed](#)]
141. Yang, X.; Wang, Y.; Lee, W.H.; Zhang, Y. Antimicrobial peptides from the venom gland of the social wasp *vespa tropica*. *Toxicon* **2013**, *74*, 151–157. [[CrossRef](#)] [[PubMed](#)]
142. Mendes, M.A.; de Souza, B.M.; Marques, M.R.; Palma, M.S. Structural and biological characterization of two novel peptides from the veom of the neotropical social wasp *agelaia pallipes pallipes*. *Toxicon* **2004**, *44*, 67–74. [[CrossRef](#)] [[PubMed](#)]
143. Li, J.; Xu, X.; Xu, C.; Zhou, W.; Zhang, K.; Yu, H.; Zhang, Y.; Zheng, Y.; Rees, H.H.; Lai, R.; et al. Anti-infection peptidomics of amphibian skin. *Mol. Cell. Proteom.* **2007**, *6*, 882–894. [[CrossRef](#)] [[PubMed](#)]
144. Subramanian, S.; Ross, N.W.; MacKinnon, S.L. Myxinidin, a novel antimicrobial peptide from the epidermal mucus of hagfish, *myxine glutinosa* L. *Mar. Biotechnol.* **2009**, *11*, 748–757. [[CrossRef](#)] [[PubMed](#)]
145. Asoodeh, A.; Zardini, H.Z.; Chamani, J. Identification and characterization of two novel antimicrobial peptides, temporin-ra and temporin-rb, from skin secretions of the marsh frog (*rana ridibunda*). *J. Pept. Sci.* **2012**, *18*, 10–16. [[CrossRef](#)] [[PubMed](#)]
146. Monincová, L.; Buděšínský, M.; Slaninová, J.; Hovorka, O.; Cvačka, J.; Voburka, Z.; Fučík, V.; Borovičková, L.; Bednárová, L.; Straka, J.; et al. Novel antimicrobial peptides from the venom of the eusocial bee *halictus sexcinctus* (hymenoptera: Halictidae) and their analogs. *Amino Acids* **2010**, *39*, 763–775. [[CrossRef](#)] [[PubMed](#)]
147. Alkotaini, B.; Anuar, N.; Kadhum, A.A.H.; Sani, A.A.A. Detection of secreted antimicrobial peptides isolated from cell-free culture supernatant of *paenibacillus alvei* an5. *J. Ind. Microbiol. Biotechnol.* **2013**, *40*, 571–579. [[CrossRef](#)] [[PubMed](#)]
148. Simmaco, M.; Mignogna, G.; Canofeni, S.; Miele, R.; Mangoni, M.L.; Barra, D. Temporins, antimicrobial peptides from the european red frog *rana temporaria*. *Eur. J. Biochem.* **1996**, *242*, 788–792. [[CrossRef](#)] [[PubMed](#)]
149. Krishnakumari, V.; Nagaraj, R. Antimicrobial and hemolytic activities of crabrolin, a 13-residue peptide from the venome of the european hornet, *vespa crabro*, and its analogues. *J. Pept. Res.* **1997**, *50*, 88–93. [[CrossRef](#)] [[PubMed](#)]
150. Falla, T.J.; Hancock, R.E. Improved activity of a synthetic indolicidin analog. *Antimicrob. Agents Chemother.* **1997**, *41*, 1997.
151. Kim, J.B.; Conlon, J.M.; Iwamuro, S.; Knoop, F.C. Antimicrobial peptides from the skin of the japanese mountain brown frog, *rana ornativentris*. *J. Pept. Res.* **2001**, *58*, 349–356. [[CrossRef](#)] [[PubMed](#)]
152. Conlon, J.M.; Sonnevend, A.; Davidson, C.; Demandt, A.; Jouenne, T. Host-defense peptides isolated from the skin secretions of the northern red-legged frog *rana aurora aurora*. *Dev. Comp. Immunol.* **2005**, *29*, 83–90. [[CrossRef](#)] [[PubMed](#)]
153. Conlon, J.M.; Abraham, B.; Sonnevend, A.; Jouenne, T.; Cosette, P.; Leprince, J.; Vaudry, H.; Bevier, C.R. Purification and characterization of antimicrobial peptides from the skin secretions of the carpenter frog *rana virgatipes* (ranidae, aquarana). *Regul. Pept.* **2005**, *131*, 38–45. [[CrossRef](#)] [[PubMed](#)]
154. Zeng, X.C.; Zhou, L.; Shi, W.; Luo, X.; Zhang, L.; Nie, Y.; Wang, J.; Shifen, W.; Cao, B.; Cao, H. Three new antimicrobial peptides from the scorpion *pandinus imperator*. *Peptides* **2013**, *45*, 28–34. [[CrossRef](#)] [[PubMed](#)]
155. Abbassi, F.; Oury, B.; Blasco, T.; Sereno, D.; Bolbach, G.; Nicolas, P.; Hani, K.; Amiche, M.; Ladram, A. Isolation, characterization and molecular cloning of new temporins from the skin of the north african ranid *pelophylax saharica*. *Peptides* **2008**, *29*, 1526–1533. [[CrossRef](#)] [[PubMed](#)]
156. Gao, B.; Sherman, P.; Luo, L.; Bowie, J.; Zhu, S. Structural and functional characterization of two genetically related meucin peptides highlights evolutionary divergence and convergence in antimicrobial peptides. *FASEB J.* **2009**, *23*, 1230–1245. [[CrossRef](#)] [[PubMed](#)]

157. Zeng, X.C.; Wang, S.X.; Zhu, Y.; Zhu, S.Y.; Li, W.X. Identification and functional characterization of novel scorpion venom peptides with no disulfide bridge from *buthus martensii* karsch. *Peptides* **2004**, *25*, 143–150. [[CrossRef](#)] [[PubMed](#)]
158. Dai, L.; Corzo, G.; Naoki, H.; Andriantsiferana, M.; Nakajima, T. Purification, structure–function analysis, and molecular characterization of novel linear peptides from scorpion *opisthacanthus madagascariensis*. *Biochem. Biophys. Res. Commun.* **2002**, *293*, 2002. [[CrossRef](#)]
159. Ramírez-Carretero, S.; Quintero-Hernández, V.; Jiménez-Vargas, J.M.; Corzo, G.; Possani, L.D.; Becerril, B.; Ortiz, E. Gene cloning and functional characterization of four novel antimicrobial-like peptides from scorpions of the family vaejovidae. *Peptides* **2012**, *34*, 290–295. [[CrossRef](#)] [[PubMed](#)]
160. Song, Y.; Ji, S.; Liu, W.; Yu, X.; Meng, Q.; Lai, R. Different expression profiles of bioactive peptides in *pelophylax nigromaculatus* from distinct regions. *Biosci. Biotechnol. Biochem.* **2013**, *77*, 1075–1079. [[CrossRef](#)] [[PubMed](#)]
161. Yang, H.; Wang, X.; Liu, X.; Wu, J.; Liu, C.; Gong, W.; Zhao, Z.; Hong, J.; Lin, D.; Wang, Y. Antioxidant peptidomics reveals novel skin antioxidant system. *Mol. Cell. Proteom.* **2009**, *8*, 571–583. [[CrossRef](#)] [[PubMed](#)]
162. Wu, S.; Nie, Y.; Zeng, X.C.; Cao, H.; Zhang, L.; Zhou, L.; Yang, Y.; Luo, X.; Liu, Y. Genomic and functional characterization of three new venom peptides from the scorpion *heterometrus spinifer*. *Peptides* **2014**, *53*, 30–41. [[CrossRef](#)] [[PubMed](#)]
163. Duval, E.; Zatylny, C.; Laurencin, M.; Baudy-Floc'h, M.; Henry, J. Kkkkplfglffglf: A cationic peptide designed to exert antibacterial activity. *Peptides* **2009**, *30*, 1608–1612. [[CrossRef](#)] [[PubMed](#)]
164. Jin, L.L.; Song, S.S.; Li, Q.; Chen, Y.H.; Wang, Q.Y.; Hou, S.T. Identification and characterisation of a novel antimicrobial polypeptide from the skin secretion of a chinese frog (*rana chensinensis*). *Int. J. Antimicrob. Agents* **2009**, *33*, 538–542. [[CrossRef](#)] [[PubMed](#)]
165. Conlon, J.M.; Al-Dhaheri, A.; Al-Mutawa, E.; Al-Kharrage, R.; Ahmed, E.; Kolodziejek, J.; Nowotny, N.; Nielsen, P.F.; Davidson, C. Peptide defenses of the cascades frog *rana cascadae*: Implications for the evolutionary history of frogs of the amerana species group. *Peptides* **2007**, *28*, 1268–1274. [[CrossRef](#)] [[PubMed](#)]
166. Chen, W.; Yang, X.; Yang, X.; Zhai, L.; Lu, Z.; Liu, J.; Yu, H. Antimicrobial peptides from the venoms of *vespa bicolor fabricus*. *Peptides* **2008**, *29*, 1887–1892. [[CrossRef](#)] [[PubMed](#)]
167. Dos Santos Cabrera, M.P.; De Souza, B.M.; Fontana, R.; Konno, K.; Palma, M.S.; De Azevedo, W.F.J.; Neto, J.R. Conformation and lytic activity of eumenine mastoparan: A new antimicrobial peptide from wasp venom. *J. Pept. Res.* **2004**, *64*, 95–103. [[CrossRef](#)] [[PubMed](#)]
168. Čerovský, V.; Slaninová, J.; Fučík, V.; Hulačová, H.; Borovičková, L.; Ježek, R.; Bednárová, L. New potent antimicrobial peptides from the venom of polistinae wasps and their analogs. *Peptides* **2008**, *29*, 992–1003. [[CrossRef](#)] [[PubMed](#)]
169. De Souza, B.M.; da Silva, A.V.R.; Resende, V.M.F.; Arcuri, H.A.; dos Santos Cabrera, M.P.; Neto, J.R.; Palma, M.S. Characterization of two novel polyfunctional mastoparan peptides from the venom of the social wasp *polybia paulista*. *Peptides* **2009**, *30*, 1387–1395. [[CrossRef](#)] [[PubMed](#)]
170. Jiravanichpaisal, P.; Lee, S.Y.; Kim, Y.A.; Andrén, T.; Söderhäll, I. Antibacterial peptides in hemocytes and hematopoietic tissue from freshwater crayfish *pacifastacus leniusculus*: Characterization and expression pattern. *Dev. Comp. Immunol.* **2007**, *31*, 441–455. [[CrossRef](#)] [[PubMed](#)]
171. Wu, J.; Liu, H.; Yang, H.; Yu, H.; You, D.; Ma, Y.; Ye, H.; Lai, R. Proteomic analysis of skin defensive factors of tree frog *hyla simplex*. *J. Proteome Res.* **2011**, *10*, 4230–4240. [[CrossRef](#)] [[PubMed](#)]
172. Kim, S.S.; Shim, M.S.; Chung, J.; Lim, D.Y.; Lee, B.J. Purification and characterization of antimicrobial peptides from the skin secretion of *rana dybowskii*. *Peptides* **2007**, *28*, 1532–1539. [[CrossRef](#)] [[PubMed](#)]
173. Konno, K.; Hisada, M.; Naoki, H.; Itagaki, Y.; Fontana, R.; Rangel, M.; Oliveira, J.S.; dos Santos Cabrera, M.P.; Neto, J.R.; Hide, I.; et al. Eumenitin, a novel antimicrobial peptide from the venom of the solitary eumenine wasp *eumenes rubronotatus*. *Peptides* **2006**, *27*, 2624–2631. [[CrossRef](#)] [[PubMed](#)]

